Company: VCYT
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001384101-25-000051
Chunk: 4

Company: VERACYTE, INC.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 4
---
              |     |                           |
|                           |     | Jens Holstein$                                                                                                    
 Chief Financial Officer, BioNTech SE                                                                              |     |  61 |     |           2020 |     | Y           |     | C                    |     |                                     |     | l            |     |                           |
|                           |     | Evan Jones$                                                                                                       
 Managing member, jVen Capital, LLC                                                                                |     |  68 |     |           2008 |     | Y           |     | l                    |     | l                                   |     |              |     | C                         |
|                           |     | Tom Miller, Ph.D.                                                                                                 
 Co-founder and Chief Executive Officer, Iambic Therapeutics                                                       |     |  46 |     |           2024 |     | Y           |     |                      |     |                                     |     |              |     | l                         |
|                           |     | Brent Shafer                                                                                                      
 Interim CEO and Chair, Baxter International, Inc. and Board of Directors member, Tactile Systems Technology, Inc. |     |  67 |     |           2024 |     | Y           |     |                      |     |                                     |     | l            |     |                           |

| lCommittee Member |     | CCommittee Chairperson |     | «Chair of the Board |     | $Audit Committee Financial Expert |

#### 4Veracyte2025 Proxy Statement

#### Proxy Statement Summary
2024 Financial and Business Highlights and Recent Company Developments

| 23%                                                         
 Increase in revenue from $361.1M in 2023 to $445.8M in 2024 |     | 152,750                                                            
 Total test volume for 2024, an increase of 20% from the prior year |     | $75.1M                                                          
 Cash generated from operating activities for the full year 2024 |     | $289.4M                             
 Cash and cash equivalents as of end 
 of year 2024                        |

• Through Level I evidence, Decipher secured its position as the only gene expression test included in V1.2025 of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer published in December 2024.

• Received approval from Molecular Diagnostic Services Program (MolDx) for the technical assessment submission for Decipher for use in the metastatic population.

• Expanded clinical evidence for Decipher Prostate with 57 publications